Analysis of common clinical adverse reactions and safe medication tips of capicitinib tablets

Capisetinib is an oral small molecule protein kinase inhibitor that mainly targets tumors with abnormal activation of the AKT signaling pathway. It especially shows potential efficacy in breast cancer, prostate cancer and some solid tumors. The AKT pathway plays a key role in the proliferation, survival and drug resistance mechanisms of tumor cells, and carpisetin inhibits tumor cell proliferation and induces apoptosis by inhibiting the phosphorylation of AKT and blocking downstream signaling pathways. During clinical application, capicitinib has shown certain efficacy, but it also has a variety of adverse reactions. Proper management of these side effects is crucial to the long-term safety of patients.

Clinical studies have shown that common adverse reactions of capiseti tablets include hyperglycemia, diarrhea, nausea, vomiting, rash and fatigue, among which elevated blood sugar is the most concerning issue. Since the AKT signaling pathway plays an important role in insulin signaling, inhibition of AKT may lead to glucose metabolism disorders, so blood glucose levels should be monitored regularly before and during treatment. For patients with significantly elevated blood sugar, intervention can be performed through diet control, oral hypoglycemic drugs, or insulin therapy to reduce the risk of complications. At the same time, patients need to pay close attention to blood sugar fluctuations and follow the doctor's recommendations to adjust drug dosage or frequency.

Gastrointestinal reactions are another common adverse reaction of capisete tablets, mainly manifesting as diarrhea, nausea, vomiting and loss of appetite. Most patients' symptoms are mild to moderate and can be relieved by taking the medicine in divided doses, taking it after meals, or using symptomatic drugs. For patients with severe or long-lasting symptoms, doctors may recommend temporarily discontinuing the drug or reducing the dose to ensure that the patient can tolerate the treatment and maintain drug effects. In addition, some patients may develop rashes or mild dry skin during use. They should pay attention to skin care and avoid scratching or using irritating skin care products to reduce the risk of secondary infection.

Other common adverse reactions include fatigue, joint pain, and mild abnormalities in hematological indicators, such as decreased platelets or leukocytes. These reactions can usually be controlled by dose adjustment, extended dosing intervals, or symptomatic treatment. Patients should undergo regular laboratory tests during the medication period, including blood routine, liver and kidney function and blood sugar monitoring, so that abnormalities can be detected early and dealt with promptly. For elderly patients or patients with underlying diseases, special attention should be paid to cardiovascular and metabolic related indicators to ensure safe medication use. In addition, while using Capisete Tablets, patients should avoid concurrent use with other drugs that may increase the burden on the liver and kidneys, and maintain a good daily routine and dietary habits to reduce the incidence of adverse reactions.

In general, carpisete tablets show good anti-tumor potential in targeted therapy, but its adverse reactions involve blood sugar metabolism, gastrointestinal reactions, skin, blood system and other aspects. Clinically, safe use needs to be ensured through regular monitoring, dose adjustment, symptomatic treatment and lifestyle intervention. Patients should fully understand possible adverse reactions before taking medication and formulate individualized treatment plans under the guidance of professional doctors to ensure the efficacy while minimizing the risk of side effects and achieving long-term tolerable targeted treatment effects.

Reference materials:https://pubmed.ncbi.nlm.nih.gov/38388873/